Pyxis Oncology (NASDAQ:PYXS) Announces Quarterly Earnings Results

Pyxis Oncology (NASDAQ:PYXS) posted its quarterly earnings data on Thursday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05), Zacks reports.

Pyxis Oncology Price Performance

Shares of Pyxis Oncology stock remained flat at $3.01 during midday trading on Friday. The company had a trading volume of 701,356 shares, compared to its average volume of 1,665,933. Pyxis Oncology has a 52 week low of $1.03 and a 52 week high of $5.55. The firm has a market cap of $190.68 million, a PE ratio of -2.13 and a beta of 1.31. The firm has a 50-day moving average price of $2.56 and a 200 day moving average price of $1.97.

Institutional Investors Weigh In On Pyxis Oncology

Several hedge funds have recently added to or reduced their stakes in the stock. Laurion Capital Management LP increased its holdings in shares of Pyxis Oncology by 32.3% during the fourth quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock valued at $5,516,000 after acquiring an additional 1,170,505 shares in the last quarter. Bank of America Corp DE boosted its stake in Pyxis Oncology by 2,690.9% in the 3rd quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock worth $1,367,000 after purchasing an additional 593,853 shares in the last quarter. Longaeva Partners L.P. bought a new position in Pyxis Oncology in the 3rd quarter worth about $1,117,000. Jane Street Group LLC grew its position in Pyxis Oncology by 158.8% during the 4th quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock valued at $904,000 after purchasing an additional 482,310 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in Pyxis Oncology during the 4th quarter valued at about $448,000. 39.07% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on PYXS shares. Weiss Ratings cut Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Wells Fargo & Company began coverage on Pyxis Oncology in a research note on Monday, August 3rd. They issued an “overweight” rating and a $12.00 price target on the stock. Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Wedbush began coverage on Pyxis Oncology in a research report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price objective for the company. Finally, Leerink Partners dropped their target price on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday, July 2nd. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $7.50.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.